GoCART follows a platform licensing and co-development model. We aim to advance one lead program in AML and MM to clinical appoval of the platform, while partnering additional indications with biotech/pharma companies using our universal CAR trunk architecture. The modular binder system enables a scalable pipeline with lower marginal development costs per indication. There will be cell products and viral vectors exclusively sold by us and target specific binder peptides, sometimes sold by us directly but maily by collaborators that want to use our platform architecture. For those, we charge a comission.
GoCART is a pre-seed biopharma company building a modular System for "AND"-Gated CAR T-cell therapy. Ends the "undruggable target" problem and reaches the 70% of cancers without specific treatment option. Aiming at AML and Multiple Myeloma as Beachheads